Long-term stability of vascular endothelial growth factor suppression time under ranibizumab treatment in age-related macular degeneration

American Journal of Ophthalmology

Volumn 156, Issue 5, 2013, Pages

  Muether, Philipp S ^a   Hermann, Manuel M ^a   Dröge, Katharina ^a   Kirchhof, Bernd ^a   Fauser, Sascha ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; VASCULOTROPIN;

ADULT; AQUEOUS HUMOR; ARTICLE; FEMALE; FOLLOW UP; HUMAN; LIMIT OF DETECTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RECURRENT DISEASE; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION;

EID: 84886045739     PISSN: 00029394     EISSN: 18791891     Source Type: Journal    
DOI: 10.1016/j.ajo.2013.06.020     Document Type: Article

References (11)

1. U. Chakravarthy, S.P. Harding, and C.A. Rogers Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial Ophthalmology 119 7 2012 1399 1411
2. D.F. Martin, M.G. Maguire, G.S. Ying, J.E. Grunwald, S.L. Fine, and G.J. Jaffe Ranibizumab and bevacizumab for neovascular age-related macular degeneration N Engl J Med 364 20 2011 1897 1908
3. P.S. Muether, M.M. Hermann, U. Viebahn, B. Kirchhof, and S. Fauser Vascular endothelial growth factor in patients with exudative age-related macular degeneration treated with ranibizumab Ophthalmology 119 10 2012 2082 2086
4. S.J. Bakri, M.R. Snyder, J.M. Reid, J.S. Pulido, M.K. Ezzat, and R.J. Singh Pharmacokinetics of intravitreal ranibizumab (Lucentis) Ophthalmology 114 12 2007 2179 2182
5. H. Funatsu, H. Yamashita, and H. Noma Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients Graefes Arch Clin Exp Ophthalmol 243 1 2005 3 8
6. H. Noma, H. Funatsu, and M. Yamasaki Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion Eye (Lond) 22 1 2008 42 48
7. P.S. Muether, R. Hoerster, M.M. Hermann, B. Kirchhof, and S. Fauser Long-term effects of ranibizumab treatment delay in neovascular age-related macular degeneration Graefes Arch Clin Exp Ophthalmol 251 2 2013 453 458
8. Muether P, Neuhann I, Buhl C, Hermann M, Kirchhof B, Fauser S. Intraocular growth factors and cytokines in patients with dry and neovascular age-related macular degeneration. Retina. doi: 10.1097/IAE.0b013e318285cd9e. 2013.03.13.
9. R. dell'Omo, M. Cassetta, and E. dell'Omo Aqueous humor levels of vascular endothelial growth factor before and after intravitreal bevacizumab in type 3 versus type 1 and 2 neovascularization. A prospective, case-control study Am J Ophthalmol 153 1 2012 155 161.e152
10. D. Smailhodzic, P.S. Muether, and J. Chen Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age-related macular degeneration Ophthalmology 119 11 2012 2304 2311
11. V.V. Lyzogubov, R.G. Tytarenko, P. Jha, J. Liu, N.S. Bora, and P.S. Bora Role of ocular complement factor H in a murine model of choroidal neovascularization Am J Pathol 177 4 2010 1870 1880